Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age

<strong>Background:</strong> A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a ‘toddler’ booster dose are essential...

Full description

Bibliographic Details
Main Authors:	Snape, M, Pollard, A, Voysey, M, Finn, A, Bona, G, Esposito, S, Principi, N, Diez-Domingo, J, Sokal, E, Kieninger, D, Prymula, R, Dull, P, Kohl, I, Barone, M, Wang, H, Toneatto, D
Format:	Journal article
Published:	Lippincott, Williams and Wilkins 2015

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age

Similar Items